• Incyte raised its 2026 net sales forecast to $5.21 billion-$5.3 billion from $5.13 billion-$5.26 billion.
• Opzelura sales guidance increased to $1.1 billion-$1.12 billion from $1.05 billion-$1.1 billion.
• Hematology and oncology sales are now projected at $890 million-$910 million, up from $860 million-$890 million.
• Jakafi sales guidance remained unchanged at $3.22 billion-$3.27 billion.
• Third-quarter net sales rose 14% to $1.32 billion; sales excluding Jakafi increased 37% to $490 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.